MaxCyte

MaxCyte® is a leading cell-engineering company advancing the discovery, development, and commercialization of next-generation cell therapies. The company's Flow Electroporation® technology and SeQure DX™ gene editing risk assessment services provide precise, efficient, and scalable solutions for cell engineering. Supported by comprehensive scientific, technical, and regulatory expertise, MaxCyte’s ExPERT™ platform enables researchers to engineer a wide range of cell types and payloads, accelerating the development of safe and effective treatments. With more than 25 years of experience in cell engineering, MaxCyte continues to shape the future of medicine.

Content by MaxCyte

Graphic showing a DNA strand and red blood cells

Moving Gene Editing Advances Into the Clinic

The ScientistandMaxCyte | | 4 min read

Page 1 of 1 - 1 Total Items

February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue

Research Resources

Podcasts

Webinars

Videos

Infographics

eBooks

Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

In this half-day virtual summit, a series of presentations will explore the scientific, regulatory, and operational factors impacting the use of in vitro NAMs in drug discovery.

Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

In this webinar, scientists will discuss innovations that are unlocking new insights into immunity.

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

In this webinar, Magdalena Pacewicz will highlight how to use AUC to characterize AAVs as part of ensuring regulatory compliance.

Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

Discover how the latest cancer research models and their applications help scientists pursue breakthrough cancer therapy research.

Products

Product News

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Chief Business Officer Dr. Rob Burgess Shares How Sino Biological Is Empowering Global Biomedical Research Through Precision, Quality, and Innovation on an Exclusive Segment on Fox Business Network airing on February 1, 2026 at 4:30pm EST

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Sino Biological, Inc. has announced the accelerated availability and development of critical research tools to support the global scientific community in combating NiV.

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Collaboration will bring next generation orchestration and modular automation to scientists worldwide

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies

The ranking places Refeyn among a cohort of high-growth UK technology firms spanning sectors including the life sciences, energy and sustainability, telecommunications, and digital technology.